Skip to main content
. 2021 Dec 23;14(1):69. doi: 10.3390/cancers14010069

Figure 5.

Figure 5

PFS by DM status and metformin treatment in (a) all patients receiving lanreotide 120 mg, (b) patients receiving lanreotide 120 mg, excluding those who developed DM after the start of treatment, (c) all patients receiving placebo and (d) patients receiving placebo, excluding those who developed DM after the start of treatment. HR: (a) DM with metformin compared with without DM: 0.94 {95%CI = 0.32; 2.77}; DM with metformin compared with DM without metformin: 1.22 {95%CI = 0.38; 3.87}; DM without metformin compared with without DM: 0.77 {95%CI = 0.33; 1.80}; (b) DM with metformin compared with without DM: 0.59 {95%CI = 0.18; 1.97}; DM with metformin compared with DM without metformin: 0.24 {95%CI = 0.07; 0.80}; DM without metformin compared with without DM: 2.50 {95%CI = 1.41; 4.44}; (c) DM with metformin compared with without DM: 1.23 {95%CI = 0.37; 4.05}; DM with metformin compared with DM without metformin: 1.81 {95%CI = 0.43; 7.71}; DM without metformin compared with without DM: 0.68 {95%CI = 0.22; 2.05}; (d) DM with metformin compared with without DM: 0.66 {95%CI = 0.20; 2.19}; DM with metformin compared with DM without metformin: 0.31 {95%CI = 0.09; 1.05}; DM without metformin compared with without DM: 2.15 {95%CI = 1.18; 3.92}. CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; NR, not reached; PFS, progression-free survival.